Cargando…

Assessment of compensated advanced chronic liver disease based on serum bile acids in chronic hepatitis B patients

Patients with chronic liver disease progressed to compensated advanced chronic liver disease (cACLD), the risk of liver-related decompensation increased significantly. This study aimed to develop prediction model based on individual bile acid (BA) profiles to identify cACLD. This study prospectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Fei, Yao, Yaning, Li, Zhen, Deng, Long, He, Ruiling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10409722/ https://www.ncbi.nlm.nih.gov/pubmed/37553441 http://dx.doi.org/10.1038/s41598-023-39977-8

Ejemplares similares

Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma
por: Xun, Zhen, et al.
Publicado: (2023)

Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept “Compensated Advanced Chronic Liver Disease”
por: Fujita, Koji, et al.
Publicado: (2021)

Modulation of bile acid profile by gut microbiota in chronic hepatitis B
por: Wang, Xiaolin, et al.
Publicado: (2020)

Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection
por: Couto, Ingrid, et al.
Publicado: (2017)

Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study
por: Wang, Haoliang, et al.
Publicado: (2016)

Therapeutic Roles of Bile Acid Signaling in Chronic Liver Diseases
por: Li, Yan, et al.
Publicado: (2018)

Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases
por: Meadows, Vik, et al.
Publicado: (2020)

Profiles of Serum Bile Acids in Liver Diseases
por: Kim, Min Ja, et al.
Publicado: (1986)

Increased Renal Clearance of Rocuronium Compensates for Chronic Loss of Bile Excretion, via upregulation of Oatp2
por: Wang, Long, et al.
Publicado: (2017)

Serum IL-21 levels associated with chronic hepatitis B and hepatitis B-related liver failure
por: CHEN, HONG-MEI, et al.
Publicado: (2014)

Chronic corticosterone exposure disrupts hepatic and intestinal bile acid metabolism in chicken
por: Wu, Lei, et al.
Publicado: (2023)

Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
por: Chen, Qingling, et al.
Publicado: (2023)

Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis
por: Iwata, Kazunari, et al.
Publicado: (2014)

Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease
por: Margini, Cristina, et al.
Publicado: (2018)

Serum markers for predicting advanced fibrosis in patients with chronic hepatitis B and nonalcoholic fatty liver disease
por: Wang, Qi, et al.
Publicado: (2021)

Plasma bile acids in healthy green iguanas and iguanas with chronic liver diseases
por: Knotek, Zdenek, et al.
Publicado: (2023)

Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection
por: Xie, Guoxiang, et al.
Publicado: (2020)

Prediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitis
por: Lee, Hong Sub, et al.
Publicado: (2010)

Serum bile acids in liver cirrhosis promote neutrophil dysfunction
por: Balazs, Irina, et al.
Publicado: (2022)

Prediction of High-Risk Varices in Patients with Compensated Advanced Chronic Liver Disease in Saudi Arabia
por: Ismail, Mona
Publicado: (2023)

Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis
por: Wu, Cheng, et al.
Publicado: (2015)

Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals
por: Pons, Mònica, et al.
Publicado: (2017)

Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Chronic hepatitis C virus infection: Relationships between inflammatory marker levels and compensated liver cirrhosis
por: Li, Xu, et al.
Publicado: (2019)

Serum Hyaluronic Acid: A Promising Marker of Hepatic Fibrosis in Chronic Hepatitis B
por: Shiha, Gamal
Publicado: (2008)

Serum Hyaluronic Acid as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis B
por: Geramizadeh, Bita, et al.
Publicado: (2008)

Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation
por: Nakajima, Atsushi, et al.
Publicado: (2022)

Altered Serum Bile Acid Profile Associated with Chronic Allograft Dysfunction in Kidney Transplant Recipients
por: Li, Yamei, et al.
Publicado: (2022)

Serum dihydroxyacetone kinase peptide m/z 520.3 as predictor of disease severity in patients with compensated chronic hepatitis B
por: Xu, Ming-Yi, et al.
Publicado: (2013)

Mouse Liver Compensates Loss of Sgpl1 by Secretion of Sphingolipids into Blood and Bile
por: Spohner, Anna Katharina, et al.
Publicado: (2021)

Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection
por: Yan, Li-Ting, et al.
Publicado: (2020)

Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure
por: Xie, Guoxiang, et al.
Publicado: (2018)

On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B
por: Chang, Xiu-Juan, et al.
Publicado: (2019)

Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B
por: Cho, Hyo Jung, et al.
Publicado: (2014)

Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China
por: Jia, Wen, et al.
Publicado: (2015)

Effect of COVID-19 on patients with compensated chronic liver diseases
por: Ji, Dong, et al.
Publicado: (2020)

Resting and postprandial serum bile acid concentrations in dogs with liver disease
por: Pena‐Ramos, Jorge, et al.
Publicado: (2021)

Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans
por: Luo, Lina, et al.
Publicado: (2018)

The Benevolent Bile: Bile Acids as Stimulants of Liver Regeneration
por: Bhushan, Bharat, et al.
Publicado: (2022)

Stool vs. Serum Hepatitis B Virus DNA in Patients with Chronic Hepatitis B
por: Zheng, Ji-shun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jpnbedfdr5brqt0ptjqhvsjpk4